Alay S. Banker, Ajay Dudani, Ashish Vaidya, Rohan Chauhan, Urvashi Goja

Advantages:

Combination therapies (half-fluence photodynamic therapy and intravitreal Anti-VEGF) lead to better chances of improved vision and fewer repeat treatments in cases of choroidal neovascularization.

Methods:

Prospective study of 36 eyes treated with single half-fluence Photodynamic therapy (PDT) + 3 monthly intravitreal ranibizumab (IL). ETDRS visual acuity (VA), fluorescein angiography and central retinal thickness(CRT) were evaluated.

Effectiveness / Safety:

At final follow-up (6-18 months, mean: 10.5) all eyes showed resolution of CNV. The mean final VA was 0.387+ 0.188 (LogMar ETDRS) versus 0.725+ 0.175 (p
0.001) at baseline. The mean final CRT was 201.36 versus 294.18 at baseline (p :
0.005). Only 6(17%) eyes required additional IL.